Pseudomonas aeruginosa has long been regarded as one of the most formidable opponents in modern medicine, a Gram-negative bacterium capable of thriving in soil, water, hospital surfaces, and the humid recesses of the human body. For patients with weakened immune systems, particularly those enduring extended stays in intensive care units, this opportunistic pathogen represents a constant threat, driving ventilator-associated pneumonia, bloodstream infections, urinary tract infections, and devastating burn wound infections. Now, a team of researchers from Lahore College for Women University in Pakistan has published a study in the journal International Microbiology that not only maps the alarming scale of multidrug resistance among clinical isolates in Lahore but also leverages computational immunology to identify promising vaccine targets hidden within the bacterium’s outer membrane. The findings arrive at a moment when clinicians worldwide are running out of effective antibiotics against this pathogen, and they offer a detailed molecular roadmap for an alternative strategy: a multi-epitope vaccine designed to outflank resistance altogether.
The research team, led by Rabia Ulfat under the supervision of Rasheeda Bashir, with co-investigators Khadeeja Abubakar and Iram Murtaza, collected 65 clinical samples between September 2024 and February 2025 from patients admitted to tertiary care hospitals across Lahore, Punjab. The specimens were drawn from four distinct infection sites: blood, urine, sputum, and burn wounds. Through a rigorous sequence of phenotypic and biochemical tests, including Gram staining, Simmons citrate, triple sugar iron, urease, and motility assays, the team confirmed Pseudomonas aeruginosa in 52 of the 65 samples. The distribution of isolates was telling: sputum accounted for 35 percent of confirmed cases, burn wounds for 30 percent, urine for 20 percent, and blood for 15 percent, a pattern that mirrors the pathogen’s well-documented affinity for the respiratory tracts and compromised skin barriers of hospitalized patients.
The antibiotic susceptibility results, obtained using the Kirby-Bauer disk diffusion method on Mueller-Hinton Agar according to Clinical and Laboratory Standards Institute 2024 guidelines, paint a sobering picture of the resistance landscape. A striking 70 percent of the confirmed isolates qualified as multidrug-resistant. Resistance to beta-lactam antibiotics was nearly universal, with penicillin and cefixime each showing 95 percent resistance, ceftriaxone at 93 percent, and meropenem, a last-line carbapenem, at a troubling 90 percent. Yet the picture was not uniformly bleak. Ciprofloxacin retained activity against 90 percent of isolates, and gentamicin, imipenem, and the cefoperazone-sulbactam combination were effective against every strain tested. The statistical analysis, performed with IBM SPSS Statistics v29, yielded a chi-square value with p less than 0.0001, underscoring that empirical prescribing in this setting is a gamble and that therapy must be guided by individual sensitivity profiles.
To probe the molecular underpinnings of both virulence and resistance, the researchers turned their attention to two conserved outer membrane genes: oprI and oprL. These genes encode outer membrane lipoproteins that perform dual duties critical to the bacterium’s survival and pathogenicity. OprI facilitates the formation of outer membrane vesicles, which serve as delivery vehicles for toxins and quorum-sensing molecules such as PQS, while OprL maintains the structural integrity of the bacterial envelope by sustaining efflux pump function and reinforcing biofilm resilience. Because these proteins sit at the interface between the bacterium and its environment, including the antibiotics deployed against it, they are simultaneously markers of identity, contributors to drug resistance, and, potentially, Achilles’ heels for immune targeting. Genomic DNA was extracted from the isolates using the phenol-chloroform method, with purity verified by NanoDrop spectrophotometry, and polymerase chain reaction amplification was carried out with primers yielding expected products of 504 base pairs for oprL and 249 base pairs for oprI.
The PCR results were remarkable in their consistency. Every one of the 52 confirmed isolates, a full 100 percent, harbored the oprL gene, while oprI was detected in 85.5 percent of strains. Representative PCR products were purified and subjected to Sanger sequencing, which confirmed their identity and revealed 98 to 100 percent similarity with reference P. aeruginosa sequences deposited in GenBank. This near-universal prevalence positions oprI and oprL not only as reliable molecular diagnostic markers for rapid identification of the pathogen, in line with previous international reports, but also as evolutionarily stable candidates for immune intervention. Multiple sequence alignment using Clustal Omega and phylogenetic tree construction with the Neighbor-Joining method in MEGA12 software demonstrated that the Pakistani clinical isolates cluster closely with international reference strains, suggesting that epitopes conserved in these Lahore isolates would likely find counterparts in P. aeruginosa populations around the world.
With the molecular groundwork laid, the team launched into an extensive in silico campaign grounded in reverse vaccinology. Protein sequences retrieved from UniProt were subjected to a battery of bioinformatic tools. VirulentPred classified oprL as non-virulent and oprI as virulent, while subcellular localization predictions from PSORTb v3.0 and Gneg-mPLoc v2.0 confirmed that both proteins reside in the outer membrane, an ideal location for antibody accessibility. DeepTMHMM analysis revealed a globular architecture with potentially surface-exposed antigenic regions, and SignalP 6.0 identified a lipoprotein signal peptide in OprL that may contribute to immune recognition, while OprL lacked such a feature in OprI. Physicochemical characterization through ProtParam showed OprI to be a small, stable, hydrophilic protein with a molecular weight of 7,799.34 daltons, a theoretical isoelectric point of 6.79, an instability index of 18.49, and a GRAVY score of −0.948, whereas OprL was larger at 16,402.95 daltons, slightly more acidic with a pI of 4.88, stable with an instability index of 34.63, and mildly hydrophobic with a GRAVY score of 0.630. Homology modeling via SWISS-MODEL, visualized in PyMOL 2.6, produced well-defined three-dimensional folds for both proteins, supporting their structural plausibility as vaccine scaffolds.
The epitope prediction pipeline represented the most technically ambitious phase of the study. Cytotoxic T lymphocyte epitopes were predicted using NetMHCpan 4.1, which generated pools of 9-mer peptides; only those with a consensus percentile rank of 1 percent or below were designated strong binders and advanced through successive safety filters. VaxiJen v2.0 assessed antigenicity with a threshold of 0.4, AllerTOP v2.1 screened for allergenicity, and ToxinPred v3.0 evaluated toxicity. Helper T lymphocyte epitopes were predicted through the Immune Epitope Database TepiTool, and the immunomodulatory potential of surviving candidates was gauged using IL4pred and IFNepitope servers, which estimate the capacity of peptides to induce the IL-4 and interferon-gamma cytokines central to orchestrating adaptive immune responses. B-cell epitopes were predicted with ABCpred and subjected to the same toxicity, allergenicity, and antigenicity gauntlet. A pivotal finding emerged from this filtering cascade: every strong-binding HTL epitope derived from oprI was predicted to be both allergic and toxic, disqualifying it from vaccine development, whereas several strong-binding HTL epitopes from oprL passed all safety screens. Conservation analysis confirmed that the surviving epitopes were fully preserved across the sequenced isolates, a critical property for a vaccine intended to provide broad protection against genetically diverse strains.
Among the OprL-derived candidates, one epitope in particular, the eight-residue peptide LTEAADTTR, drew attention for its structural behavior. Predicted conformations generated with PEP-FOLD3 and rendered in PyMOL revealed a clear helical tendency with limited disordered regions, a configuration associated with enhanced peptide stability and improved binding to major histocompatibility complex class II molecules. Stable peptide-MHC complexes are more effectively recognized by T cell receptors, which in turn promotes a more robust and durable immune response. The researchers also noted that the failure of OprI’s helper T cell epitopes to clear the safety filters, despite the protein’s outer membrane localization and antigenic promise, suggests that regions of OprI involved in tightly maintaining membrane integrity and host interaction may harbor immunologically risky motifs. Alternate or allele-specific regions of OprI, they propose, may warrant further exploration, but the immediate priority for vaccine construction lies with OprL.
The authors are careful to frame their conclusions within the limits of computational prediction. The entire vaccine candidacy assessment rests on in silico tools that illuminate antigenicity, epitope conservation, and immune recognition potential but cannot substitute for empirical evidence. The proposed multi-epitope construct, they emphasize, must be assembled with appropriate linkers and adjuvants, subjected to molecular docking against MHC molecules and immune receptors, and ultimately validated through both in vitro and in vivo experiments to confirm protective efficacy and immunogenicity. Nevertheless, the integration of molecular characterization with computational analysis carries a distinctive strength: every proposed vaccine target is derived directly from clinically circulating multidrug-resistant isolates rather than from laboratory reference strains alone, anchoring the immunoinformatic predictions in the epidemiological reality of Pakistani hospitals.
The broader significance of the study extends beyond vaccine design. The 70 percent multidrug resistance rate documented in Lahore, coupled with near-total resistance to beta-lactams and alarming resistance to the carbapenem meropenem, adds to a growing body of evidence that antimicrobial resistance in P. aeruginosa is accelerating in South Asian healthcare settings, driven in part by widespread and often inappropriate antibiotic use. Resistance mechanisms such as efflux pumps, beta-lactamase production, aminoglycoside-modifying enzymes, and porin mutations allow the pathogen to withstand extreme antibiotic pressure and persist in clinical environments, while its capacity for biofilm formation shields it from both host defenses and antimicrobial treatment. The complete susceptibility to gentamicin and imipenem observed in this cohort offers clinicians in the region a temporary therapeutic foothold, though the authors caution that careful stewardship is essential to preserve it.
In the end, the Lahore study encapsulates a strategy increasingly embraced by the global vaccinology community: when drugs fail, target the conserved molecular architecture of the pathogen itself. By demonstrating that oprL is universally present, safely immunogenic at the epitope level, structurally stable, and evolutionarily conserved across local and international strains, the researchers have laid the conceptual foundation for a multi-epitope subunit vaccine that could one day protect the most vulnerable patients, the immunocompromised, the burned, the ventilated, from an adversary that antibiotics are steadily losing the power to defeat. Whether the computational promise survives the crucible of laboratory and animal testing remains to be seen, but the molecular blueprint is now on the table, and the clock against multidrug resistance is ticking.
Subject of Research: Molecular and immunoinformatic characterization of the conserved outer membrane genes oprI and oprL in multidrug-resistant clinical isolates of Pseudomonas aeruginosa from Lahore, Pakistan, as potential multi-epitope vaccine targets.
Subject of Research: Biology
Article Title: Molecular and computational analysis of conserved outer membranes (oprI and oprL) in MDR clinical isolates of Pseudomonas aeruginosa as potential vaccine targets from Lahore, Pakistan
Article References: Ulfat, R., Bashir, R., Abubakar, K., & Murtaza, I. (2026). Molecular and computational analysis of conserved outer membranes (oprI and oprL) in MDR clinical isolates of Pseudomonas aeruginosa as potential vaccine targets from Lahore, Pakistan. International Microbiology. https://doi.org/10.1007/s10123-026-00822-3
Image Credits: AI Generated
DOI: 10.1007/s10123-026-00822-3
Keywords: Pseudomonas aeruginosa, multidrug resistance, oprI, oprL, virulence genes, PCR, reverse vaccinology, multi-epitope vaccine design, immunoinformatics, B-cell epitopes, T-cell epitopes, antimicrobial resistance
Cite Scienmag News
APA MLA Chicago
Kristina Jarvis. (September 4, 2026). Conserved Pseudomonas aeruginosa outer membrane proteins show vaccine potential in Pakistani isolates. Scienmag. https://scienmag.com/conserved-pseudomonas-aeruginosa-outer-membrane-proteins-show-vaccine-potential-in-pakistani-isolates/
Kristina Jarvis. “Conserved Pseudomonas aeruginosa outer membrane proteins show vaccine potential in Pakistani isolates.” Scienmag, 4 September 2026, https://scienmag.com/conserved-pseudomonas-aeruginosa-outer-membrane-proteins-show-vaccine-potential-in-pakistani-isolates/. Accessed 4 September 2026.
Kristina Jarvis. “Conserved Pseudomonas aeruginosa outer membrane proteins show vaccine potential in Pakistani isolates.” Scienmag. September 4, 2026. https://scienmag.com/conserved-pseudomonas-aeruginosa-outer-membrane-proteins-show-vaccine-potential-in-pakistani-isolates/
Copy citation Download RIS
Tags: antibiotic resistance challengesantibiotic resistance mitigation strategiescomputational immunology for vaccine targetscomputational immunology in vaccine designconserved outer membrane proteinsGram-negative bacterial pathogenshospital-acquired infectionsimmune response targeting Pseudomonasimmunogenic outer membrane proteinsLahore clinical microbiologymolecular mapping of bacterial proteinsmulti-epitope vaccine designmulti-epitope vaccine strategiesmultidrug resistance in clinical isolatesmultidrug resistance in Pseudomonasopportunistic bacterial infectionsopportunistic infections in immunocompromised patientsPakistan Pseudomonas researchPakistani clinical isolates of PseudomonasPseudomonas aeruginosa vaccine development
